Bringing hope through science
Webcast - OCEAN topline results
Oncopeptides presented positive topline results from the phase 3 OCEAN and hosted a webcast May 25, 2021, at 11:00 (CET).
The webcast included presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker and Anders Martin-Löf CFO. The webcast was recorded.
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more
Released
Interim report Q1 2021
”A strong start for PEPAXTO in the US”
CEO Marty J Duvall
See the Webcast
For further information, please contact:
Linda Holmström
Director of Investor Relations
linda.holmstrom@oncopeptides.com
+46 70 873 40 95
Press release -
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
Read press releaseLatest press releases
Upcoming events
-
-
-
08:00 CET
-
-
-
08:00 CET
Released
Annual Report 2020
“The past year was a transformational year for Oncopeptides highlighted by the FDA´s priority review of our NDA submission, which paved the way for an accelerated approval in the U.S. in early 2021.”
Marty J Duvall, CEO
Click here to watch the film where CEO Marty J Duvall summarizes a transformational year.
Annual Report 2020 - online version
For further information, please contact:
Linda Holmström
Director of Investor Relations
linda.holmstrom@oncopeptides.com
+46 70 873 40 95
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Seminar at the Embassy of Sweden Washington DC
The Embassy of Sweden in Washington DC, Oncopeptides AB, Dana Farber and Uppsala University hosted a virtual seminar on February 2nd,“A Swedish American Journey of Cancer Research”.
Cultures & Values
We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.